Abiraterone Acetate: all 143 studies that test it

Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.

• Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingNCT07717268Phase 2
• Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingNCT07650240Phase 2
• Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)RecruitingNCT07001709Phase 4
• Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPCNot yet recruitingNCT06768255Phase 3
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingNCT06632977Phase 2
• Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.Not yet recruitingNCT06500247Phase 2
• Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Not yet recruitingNCT06099990Phase 1
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingNCT05593497Phase 2
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingNCT05422911Phase 2
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingNCT04734730Phase 2
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyRecruitingNCT04175431Phase 2
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
• Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerRecruitingNCT03833921Phase 2
• PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)TerminatedNCT04556617Phase 1/2Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)Active, not recruitingNCT04497844Phase 3Results posted
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTerminatedNCT03999515Phase 2Results posted
• Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate CancerTerminatedNCT03827473Phase 2Results posted
• Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedNCT03777982Phase 3Results posted
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingNCT03748641Phase 3Results posted
• Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate CancerCompletedNCT03565835Phase 2Results posted
• Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate CancerCompletedNCT03279250Phase 2Results posted
• Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate CancerCompletedNCT03098836Phase 2Results posted
• A Study of Definitive Therapy to Treat Prostate Cancer After ProstatectomyCompletedNCT03043807Phase 2Results posted
• Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedNCT03007732Phase 2Results posted
• One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™CompletedNCT02962284Phase 2Results posted
• Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing ProstatectomyCompletedNCT02903368Phase 2Results posted
• Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)CompletedNCT02903160Phase 2Results posted
• A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomyCompletedNCT02849990Phase 2Results posted
• A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT02737332Phase 2Results posted
• Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1TerminatedNCT02574910Phase 1Results posted
• Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentCompletedNCT02485691Phase 4Results posted
• Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateCompletedNCT02268175Phase 2Results posted
• Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol TherapyCompletedNCT02217566Phase 2Results posted
• RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)CompletedNCT02090114Phase 2Results posted
• A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)CompletedNCT02034552Phase 2Results posted
• Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate CancerCompletedNCT02025010Phase 2Results posted
• Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)TerminatedNCT01994590Phase 2Results posted
• Abiraterone Race in Metastatic Castrate-resistant Prostate CancerCompletedNCT01940276Phase 2Results posted
• Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT01848067Phase 1/2Results posted
• Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate CancerTerminatedNCT01845792Phase 2Results posted
• 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical ProstatectomyCompletedNCT01751451Phase 2Results posted
• Abiraterone Acetate Trial in African American Prostate Cancer PatientsTerminatedNCT01735396Phase 2Results posted
• A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate CancerTerminatedNCT01717898Phase 1/2Results posted
• Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate CancerCompletedNCT01717053Phase 2Results posted
• A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)CompletedNCT01715285Phase 3Results posted
• A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based ChemotherapyCompletedNCT01695135Phase 3Results posted
• A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate CancerCompletedNCT01685983Phase 2Results posted
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsCompletedNCT01650194Phase 2Results posted
• A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate CancerCompletedNCT01637402Phase 2Results posted
• Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate CancerCompletedNCT01543776Phase 2Results posted
• A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone AcetateCompletedNCT01517802Phase 3Results posted
• Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate CancerCompletedNCT01511536Phase 1/2Results posted
• Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedNCT01503229Phase 2Results posted
• Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerCompletedNCT01487863Phase 2Results posted
• Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate CancerCompletedNCT01393730Phase 2Results posted
• A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyCompletedNCT01381874Phase 2Results posted
• S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone TherapyCompletedNCT01309672Phase 2Results posted
• Abiraterone Post Ketoconazole for Prostate CancerCompletedNCT01199146Phase 2Results posted
• Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate CancerCompletedNCT01088529Phase 2Results posted
• Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate CancerCompletedNCT01023061Phase 2Results posted
• Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT00887198Phase 3Results posted
• Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT00638690Phase 3Results posted
• An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow PlasmaCompletedNCT00544440Phase 2Results posted
• An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyCompletedNCT00485303Phase 2Results posted
• An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyCompletedNCT00474383Phase 2Results posted
• A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone TherapyCompletedNCT00473512Phase 1/2Results posted
• Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair AlterationsWithdrawnNCT06392841Phase 2
• Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant AbirateroneActive, not recruitingNCT06384222Phase 2
• Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate CancerActive, not recruitingNCT06369610Phase 2
• Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer PatientsActive, not recruitingNCT06193993Phase 1
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male SubjectsCompletedNCT06014853Phase 1
• To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate CancerTerminatedNCT05405439Phase 1/2
• A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)TerminatedNCT05295927Phase 1
• Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST TrialActive, not recruitingNCT05223582Phase 2
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerStatus unknownNCT05212857Phase 2
• The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene MutationStatus unknownNCT05167175Phase 2
• A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male VolunteersCompletedNCT04889651Phase 1
• Phase 1 Study of ATRS-2002 in Healthy Male AdultsWithdrawnNCT04879589Phase 1
• Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese VolunteersCompletedNCT04863105Phase 1
• Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate CancerCompletedNCT04862091Phase 2
• Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the ProstateStatus unknownNCT04736108Phase 2
• Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese AdultsStatus unknownNCT04735913Early Phase 1
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04691804Phase 3
• A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingNCT04577833Phase 1
• Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1
• Abiraterone Acetate in Combination With TildrakizumabTerminatedNCT04458311Phase 1/2
• Oral EPI-7386 in Patients with Castration-Resistant Prostate CancerTerminatedNCT04421222Phase 1
• Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate CancerStatus unknownNCT04356430Phase 2
• Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on AbirateroneWithdrawnNCT04296578Phase 1
• A Study Designed to Evaluate the Pharmacokinetic Profile of AbirateroneCompletedNCT04295161Phase 1
• PK and Dose Escalation and Expansion Study of DST-2970TerminatedNCT04291664Phase 1
• Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate CancerActive, not recruitingNCT04267887Phase 2
• A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerActive, not recruitingNCT04194554Phase 1/2
• Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate CancerCompletedNCT04056754Phase 3
• Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerActive, not recruitingNCT03902951Phase 2
• Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerActive, not recruitingNCT03821792Phase 2
• Androgen Reduction in Congenital Adrenal HyperplasiaWithdrawnNCT03548246Phase 2
• Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaActive, not recruitingNCT03436654Phase 2

← Abiraterone Acetate overview